Valproic acid downregulates angiotensin-converting enzyme 2 in endothelial cells,33 and several studies have shown that the downregulation of membrane-bound angiotensin-converting enzyme 2 may impair immune function and contribute to poor outcomes in the setting of COVID-19 infection.34 Additional factors may confound the association between valproic acid use and COVID-19 risk. The gene discussed is ACE2; the disease is COVID-19.